Albumin-Bound Paclitaxel: all 674 studies that test it

Page 1 of 7. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.

• MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07885709Phase 2
• PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingNCT07877584Phase 3
• Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingNCT07876154Phase 2
• Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic CancerNot yet recruitingNCT07831330Phase 2
• Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.Not yet recruitingNCT07808567Phase 2
• Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingNCT07805954Phase 3
• Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerNot yet recruitingNCT07763496Phase 2
• Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruitingNCT07752550Phase 2
• Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal CarcinomaNot yet recruitingNCT07752394Phase 2
• Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal CancerRecruitingNCT07751055Phase 2
• Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Phase 2
• DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic CancerRecruitingNCT07705919Phase 1/2
• A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic CancerRecruitingNCT07701486Phase 1/2
• An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract MalignanciesRecruitingNCT07668453Phase 2
• Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic CancerNot yet recruitingNCT07665684Phase 1/2
• A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung CancerRecruitingNCT07647094Phase 2
• Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNot yet recruitingNCT07628062Phase 2
• Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma.Not yet recruitingNCT07616362Phase 2
• Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction CancerNot yet recruitingNCT07610629Phase 2
• Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLCNot yet recruitingNCT07547332Phase 2
• Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07533305Phase 2
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT07491445Phase 3
• Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCCNot yet recruitingNCT07490002Phase 2
• IBI343 in Combination Therapy for Advanced Malignant Solid TumorsRecruitingNCT07483554Phase 2
• Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingNCT07475234Phase 1/2
• 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial TumorsNot yet recruitingNCT07463313Phase 2/3
• Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCCRecruitingNCT07452601Phase 2
• Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT07436741Phase 3
• Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.RecruitingNCT07394387Phase 2
• Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell CarcinomaRecruitingNCT07371611Phase 3
• IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric CancerNot yet recruitingNCT07361991Phase 1/2
• Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue CancerNot yet recruitingNCT07346807Phase 2
• Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingNCT07340398Phase 2
• Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric CancerRecruitingNCT07320586Phase 2
• Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)RecruitingNCT07317609Phase 1
• A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.Not yet recruitingNCT07307443Phase 2
• HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid TumorsRecruitingNCT07296341Phase 1/2
• Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT07259317Phase 2
• Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic AdenocarcinomaRecruitingNCT07253662Phase 1
• Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerRecruitingNCT07233252Phase 2
• BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingNCT07226856Phase 2
• A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Not yet recruitingNCT07200947Phase 2
• Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT07163273Phase 2
• Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUCRecruitingNCT07126119Phase 2
• Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral CancerRecruitingNCT07125547Phase 2
• Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer PatientsRecruitingNCT07096869Phase 1
• Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT07096362Phase 2
• Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic AdenocarcinomaRecruitingNCT07076212Phase 2
• Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingNCT07057427Phase 3
• 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDACRecruitingNCT07043270Phase 2
• Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric CancerNot yet recruitingNCT07018063Phase 2
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06996782Phase 1/2
• A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingNCT06953999Phase 3
• SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCRecruitingNCT06927180Phase 2
• Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaEnrolling by invitationNCT06901622Phase 2
• Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.RecruitingNCT06897644Phase 3
• A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06894459Phase 2
• A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal CancerRecruitingNCT06869226Phase 2
• Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCCNot yet recruitingNCT06861894Phase 2
• Second-line Immunotherapy for ES-SCLCRecruitingNCT06853678Not applicable
• HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
• Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJRecruitingNCT06808971Phase 2
• A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCCNot yet recruitingNCT06793761Phase 2
• Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ CancerRecruitingNCT06791148Phase 2
• Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic CancerRecruitingNCT06789679Phase 2
• A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast CancerNot yet recruitingNCT06746870Phase 2
• Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06728618Phase 2
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal MetastasesRecruitingNCT06675136Phase 1
• Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line TreatmentNot yet recruitingNCT06662877Phase 2/3
• IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialRecruitingNCT06654011Phase 2
• Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)Not yet recruitingNCT06621095Phase 2
• Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal CarcinomaRecruitingNCT06611150Phase 1
• Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerRecruitingNCT06591650Phase 2
• Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic CancerRecruitingNCT06576115Phase 2
• Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCANot yet recruitingNCT06569225Phase 2
• Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical StudyRecruitingNCT06538896Phase 2
• Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLCRecruitingNCT06532591Phase 2
• Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCCNot yet recruitingNCT06508229Phase 2
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelRecruitingNCT06483555Phase 1/2
• AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDACRecruitingNCT06472037Phase 2
• Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLCRecruitingNCT06467617Phase 2
• Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Phase 2
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingNCT06445062Phase 1/2
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast CancerRecruitingNCT06441890Phase 2
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
• Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.Not yet recruitingNCT06426056Phase 2
• Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT06423326Phase 2
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast CancerNot yet recruitingNCT06404736Phase 2
• Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal CancerRecruitingNCT06403878Phase 2
• Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical CancerRecruitingNCT06391190Phase 1/2
• Newly Emerging Immunotherapy for Pancreatic Cancer TreatmentNot yet recruitingNCT06370754Phase 1/2
• PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence PatientsRecruitingNCT06359275Phase 2
• Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT06331845Phase 2
• Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical CancerRecruitingNCT06289751Phase 2
• Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACCRecruitingNCT06288373Phase 2/3
• Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT06235918Phase 2
• Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJANot yet recruitingNCT06222944Phase 2
• Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving SurgeryRecruitingNCT06209294Phase 2
• Transcatheter Arterial Infusion to Patients With Advanced Pancreatic CancerRecruitingNCT06196788Phase 2

← Albumin-Bound Paclitaxel overview